VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies.
Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance. This matters because it addresses a critical challenge in drug development: the need for more human-relevant testing methods that can predict clinical outcomes while minimizing reliance on animal models.
The implications are significant. By aligning with FDA’s evolving framework for NAMs, VERAXA positions itself at the forefront of a regulatory shift that encourages innovative, human-relevant testing. This could lead to faster approvals and more efficient resource allocation. Moreover, the reduction in animal use—from over 200 mice to about 10—demonstrates a scalable model that other biotechs may follow, potentially transforming industry standards.
Investors and industry watchers can view the full press release at https://ibn.fm/9YRJw. For ongoing updates, the company’s newsroom is available at http://ibn.fm/VRXA. BioMedWire, a specialized communications platform for the biotech and life sciences sectors, is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. As the biotech industry increasingly embraces alternatives to animal testing, VERAXA’s progress with NAMs could set a precedent for regulatory acceptance and drive broader adoption, ultimately benefiting patients through faster access to innovative therapies.
